The randomized, controlled study showed that the human papillomavirus, HPV, test is more sensitive than the Pap smear, a widely used test that has been a standard part of women’s preventive health care for decades.
A test for HPV detects precancerous changes of the cervix earlier and more accurately than the Pap smear, according to a large clinical trial published this week.
The randomized, controlled study — the “gold standard” of research — showed that the human papillomavirus, or HPV, test is more sensitive than the Pap smear, a widely used test that has been a standard part of women’s preventive health care for decades.
Several experts predicted the results would spur efforts to replace the Pap test with the HPV test. “It’s an important study,” said Jason Wright, a gynecologic oncologist at NewYork-Presbyterian/Columbia University Medical Center who was not involved in the study. “It shows that doing HPV testing alone provides a high degree of accuracy” on who might be at risk for cervical cancer.
The HPV infection is the most common sexually transmitted infection and is usually eliminated by the immune system within a year or two. But when an infection persists, it can cause cellular changes that develop into precancerous lesions and, eventually, malignancies. Almost all cases of cervical cancer are caused by HPV infections.
Most Read Nation & World Stories
- New round of US-China tariffs raise fears of an economic Cold War
- Trump Jr. mocks sexual assault claim against Kavanaugh
- Grizzly's rare aggressive attack kills 1, puzzles officials
- Kavanaugh's accuser wants FBI probe before she testifies WATCH
- Hearing sets up dramatic showdown between Kavanaugh, accuser WATCH
About 13,240 new cases of invasive cervical cancer will be diagnosed in the United States in 2018, according to the American Cancer Society. About 4,200 women will die of the disease.
The study bolsters previous research that showed that HPV testing was superior to Pap tests. In the past several years, as experts learned more about HPV’s role in cervical cancer, most medical groups have recommended that women in the United States get both the HPV test and the Pap smear, a practice called “co-testing.” Now, armed with the new study and previous ones, some experts say the Pap smear should be dropped. Others disagree, saying the Pap smear can catch a small number of cases of abnormal cells that might be missed by the HPV test and that co-testing should continue.
Many medical groups have said that before moving to HPV testing only, they needed to see clinical-trial results — such as the kind provided by the new study — to determine which test, over time, was better at detecting the precancerous changes. These conditions can be treated before they progress to cervical cancer.
Kathleen Schmeler, a gynecological oncologist at MD Anderson Cancer Center who was not involved in the study, was enthused about the new results. “It’s fantastic,” she said. “What this shows is that you could potentially do just the HPV test and move toward getting rid of the Pap test.”
But Mark Spitzer, a gynecologist in New Hyde Park, New York, and past president of the American Society for Colposcopy and Cervical Pathology, disagreed. He said that although the study confirmed previous research showing that the HPV test is more sensitive than the Pap test, it didn’t answer a critical question: Is the HPV test alone better than the HPV test and the Pap smear together, as is current practice?
In the United States, the conventional Pap smear has been largely replaced by a liquid-based Pap cytology test. Cervical cells for both the Pap and HPV tests can be collected at the same time, during a pelvic exam. Some women might not even realize that they are being tested for HPV.
The decadelong study, published in The Journal of the American Medical Association, involved about 19,000 women who were placed in two groups: one using the HPV test to screen for cervical cancer, and the other using Pap cytology. In 2017, the researchers running the study reported that there were significantly more cases of precancerous lesions detected early in the trial among the women in the HPV-tested group, compared with the Pap cytology group.
Tuesday’s report detailed the “exit” results of the study 48 months after the women were enrolled and first screened. For those final results, both groups were tested using both the HPV test and the Pap test.
The researchers reported that there were fewer cases of precancer in the HPV test group, compared with the Pap smear group. That’s because cases of worrisome cellular changes already had been detected and dealt with after the women were first screened, said lead author Gina Ogilvie, a physician and public-health researcher at the University of British Columbia. “The real benefit of co-testing is with the HPV test,” she said.
The report, funded by the Canadian Institute of Health Research, noted that adding HPV testing to the Pap test group resulted in finding 25 lesions that would have not been found by the Pap test alone. By adding the Pap test to the HPV group, an additional three lesions were found.
Spitzer said those three cases support the “small but significant benefit of co-testing.”